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Atrial natriuretic peptide (ANP) has various pharmaco-logic effects, such as natriuresis, diuresis, vasodila-tion, inhibition of the renin-angiotensin-aldosteronesystem (RAAS) and sympathetic nervous system, and
renal protection.1,2 ANP is stored in secretory granules in the atria,
and its secretion is predominantly regulated by stretching of the
atria.3 Plasma levels of ANP increase with the severity of heart
failure,3,4 especially in patients with mitral stenosis (MS), and
there has been a significant correlation between plasma ANP
concentrations and pulmonary capillary wedge pressure.5 On the
other hand, a few cases of very low plasma ANP level despite
chronic congestive heart failure have been reported.6,7 For these
patients, the infusion of synthetic human -ANP (h-ANP) is
thought to be effective in postoperative management, although it
seems difficult to wean the patient from the h-ANP infusion.6 Here
we describe the case of a patient with a very low plasma ANP
concentration and giant atria as a result of severe MS and tricuspid
regurgitation (TR), and we report the effects of postoperative
h-ANP infusion and oral spironolactone administration for the
replacement of intravenous h-ANP infusion after cardiac surgery.
Clinical Summary
A 64-year-old woman who had undergone closed mitral commis-
surotomy for MS at the age of 29 years was admitted to our
hospital because of severe general malaise, palpitations, orthopnea,
hepatocardiomegaly, and dyspnea. These symptoms appeared even
at rest, and her New York Heart Association functional class was
III. An electrocardiogram demonstrated atrial fibrillation but
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showed no myocardial ischemic signs. A chest radiograph showed
severe pulmonary congestion, pleural effusion, and cardiomegaly
(cardiothoracic ratio 90%), indicative of chronic congestive heart
failure. On echocardiography, the left atrial dimension measured
87 mm, the left ventricular end-diastolic and end-systolic dimen-
sions measured 43 and 29 mm, respectively, the intraventricular
septal thickness measured 7 mm, the left ventricular posterior wall
thickness measured 7 mm, the fractional shortening was 33%, and
the ejection fraction was 56%. The mitral valve area was 0.66 cm2
according to the pressure half-time method and 0.59 cm2 according
to the trace method. Mitral regurgitation was mild. TR was severe,
accompanying the enlargement of both the atria. The pulmonary
arterial systolic pressure, as calculated by the peak velocity of
severe TR (39 mm Hg), was considered to represent severe pul-
monary hypertension. Cardiac catheterization and angiography
were performed for preoperative evaluation. Neither aortic stenosis
nor aortic regurgitation was detected. Left ventricular function, as
calculated by left ventriculography, was as follows: left ventricular
end-diastolic volume, 207 mL; indexed left ventricular end-dia-
stolic volume, 156 mL/m2; left ventricular end-systolic volume, 78
mL; indexed left ventricular end-systolic volume, 59 mL/m2; and
ejection fraction, 62%. Pulmonary capillary wedge pressure was
measured at 20 mm Hg, and pulmonary arterial pressure was
measured at 50/25 mm Hg (mean 33 mm Hg). Coronary angiog-
raphy showed no significant coronary artery stenosis. The diagno-
sis was therefore congestive heart failure as a result of severe MS
and TR.
To evaluate the association of neurohormones, the plasma
levels of ANP, brain natriuretic peptide (BNP), cyclic guanosine
monophosphate, renin activity, and aldosterone were measured by
radioimmunoassay. The plasma ANP concentration was very low
(7.3 pg/mL), whereas the plasma BNP concentration was high
(82.7 pg/mL). The cyclic guanosine monophosphate level was 3.2
pmol/mL. The RAAS was remarkably activated (renin activity
17.4 ng/[mL  h], plasma aldosterone 431 pg/mL). Renal function
was within normal limits, with a 0.5 mg/dL creatinine level.
The patient underwent mitral valve replacement and tricuspid
annuloplasty 35 days after admission to our institution. Median full
sternotomy was done to expose the pericardial cavity. The walls of
both the atria were remarkably thinned. Cardiopulmonary bypass
(CPB) was established in a routine fashion, and myocardial pro-
tection during aortic crossclamping was performed with continu-
ous and intermittent bolus infusions of minimally diluted blood
cardioplegia containing 9.8 mmol/L potassium and 4.0 mmol/L
magnesium. Mitral valve replacement was performed with a
27-mm bioprosthesis (Carpentier-Edwards; Baxter Healthcare
Corporation CardioVascular Group, Irvine, Calif), and tricuspid
annuloplasty was performed with a 28-mm annular ring (Cosgrove
Edwards Ring; Baxter Healthcare Corporation CardioVascular
Group). The operation was finished without any complications,
and the process of weaning the patient from CPB with the assis-
tance of inotropic agents was uneventful. After the termination of
CPB, however, oliguria developed and did not even respond to the
intravenous bolus injection of 100 mg furosemide. Intravenous
infusion of h-ANP (HANP; Suntory Inc, Zeria Pharmaceutical,
Tokyo, Japan) at a rate of 0.05 g/(kg  min) was started imme-
diately. After this infusion, systolic aortic pressure decreased to
less than 90 mm Hg, and the infusion was therefore reduced to a
rate of 0.025 g/(kg  min). The urinary output increased dramat-
ically without the use of furosemide.
Successful extubation was accomplished 11 hours after the
operation. The h-ANP infusion was gradually tapered with the use
of furosemide and was discontinued 43 hours after the operation.
Soon after cessation of h-ANP infusion, however, the urinary
volume decreased and oliguria resumed despite the dose of furo-
semide. Further h-ANP infusion at 0.025 g/(kg  min) was re-
started 34 hours after the initial discontinuance. At that time,
plasma levels of renin activity, angiotensin II, and aldosterone
remained high. A 100-mg dose of spironolactone as well as furo-
semide was administered orally to aid in tapering the h-ANP
infusion. Five days after oral spironolactone administration,
h-ANP infusion was discontinued successfully. Figure 1 illustrates
the entire postoperative course with respect to h-ANP dose and
neurohormones. The patient was discharged from our institution
50 days after the operation, at which time the plasma ANP level
was 10.2 pg/mL, the plasma BNP level was 148.5 pg/mL, and the
plasma aldosterone level was 158 pg/mL.
Discussion
The plasma ANP concentration is thought to increase in accor-
dance with the severity of chronic congestive heart failure because
the atrial distention stimulates ANP secretion,3,4 whereas some
patients with severe TR and pulmonary hypertension resulting
from MS are reported to show a very low plasma ANP concen-
tration or a lack of ANP secretion despite chronic congestive heart
failure.6,7 Nishimura and associates6 have suggested that sustained
MS and TR induce excessive extension of the atria, which might
further diminish the granules producing ANP. Maeda and col-
leagues7 demonstrated remarkable fibrosis in the histologic spec-
imen of the right atrial myocardium obtained from a patient with
MS and a very low plasma ANP concentration, with only a few
remaining myocytes and a few ANP-containing cells. However,
these two patients had undergone open mitral commissurotomy.
Nishimura and coworkers8 demonstrated in experimental heart
failure models that the secretary function of ANP was impaired
after resection of atrial appendages. Although the walls of both
atria were remarkably thinned in our case, the right atrial append-
age had not been removed or ligated. Further clinical and experi-
mental studies are needed to elucidate the mechanism of low
plasma ANP concentration in patients with severe MS, TR, and
pulmonary hypertension.
ANP has various pharmacologic effects, as mentioned previ-
ously, although it remains unclear why its secretion is enhanced
during congestive heart failure. In general, heart failure activates
the RAAS and enhances the production of vasopressin.9 Some
suggests that the enhanced ANP production in congestive heart
failure is an adaptive response to attenuate the RAAS activation
and vasopressin-induced vasoconstriction.10 On the other hand,
BNP secretion is considered to increase in accordance with the
degree of left ventricular end-diastolic pressure because the ven-
tricular distention stimulates BNP secretion.11 In patients with MS
and severe pulmonary hypertension, BNP production is thought to
increase as a result of right ventricular stimulation. In patients with
a very low plasma ANP concentration or a lack of ANP secretion,
BNP production is enhanced to compensate for the insufficient
ANP secretion.
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CPB is also thought to activate the RAAS and vasopressin
production.12 Furthermore, venous drainage reduces the atrial
stretching, resulting in a decrease in ANP production.13 Generally,
ANP production resumes at the termination of CPB in accordance
with the arterial stretching and plays a role in attenuating the
RAAS activation.13 Sezai and associates13 have demonstrated that
the RAAS activation reaches a peak 3 to 6 hours after CPB. In
patients with chronic congestive heart failure accompanying insuf-
ficient ANP secretion, however, the RAAS is thought to continue
to be activated long after the termination of CPB. This may
account for the efficacy of continuous h-ANP infusion and the
difficulty in the weaning process.
Continuous h-ANP infusion affects plasma BNP concentra-
tions. The inactivation of members of the natriuretic peptide family
is mainly associated with the following two factors: natriuretic
peptide receptor C and neutral endopeptidase.14,15 Continuous
h-ANP infusion occupies these deleting systems and reduces the
clearance of BNP, resulting in an increase in the plasma BNP
concentration. After the termination of h-ANP infusion, however,
the deleting system is immediately resumed, and the plasma BNP
concentration subsequently decreases. These biochemical re-
sponses may play a role in the rebound phenomenon seen with the
discontinuation of long-term h-ANP infusion.
According to this and previous reports, continuous h-ANP
infusion after cardiac surgery in cases of congestive heart failure
seems essential, especially for patients with insufficient ANP se-
cretion.6,7 However, there are no oral substitute drugs to aid in
discontinuing h-ANP infusion. In our case, the RAAS was still
activated at the first weaning process from intravenous h-ANP
infusion, and oral spironolactone administration was effective for
the second weaning process. Recently, several studies have dem-
onstrated the various effects of spironolactone on the patient
Figure 1. Changes in plasma levels of (A) ANP (circles), BNP (triangles), and cyclic guanosine monophosphate
(cGMP, squares) and (B) renin activity (diamonds) and aldosterone (circles). Time points are as follows: 1, before
operation; 2, 1 hour after initiation of CPB; 3, just after termination of CPB; 4, 1 hour after termination of CPB (just
before starting h-ANP infusion; 5, 3 hours after starting h-ANP infusion at 0.05 g/(kg  min); 6, 3 hours after starting
h-ANP infusion at 0.025 g/(kg  min); 7, just before restarting h-ANP infusion; 8, 3 hours after restarting h-ANP
infusion; 9, 3 hours after second termination of h-ANP infusion (with oral spironolactone administration); 10, at
discharge; 11, 3 months after the operation.
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management in cardiovascular care.16,17 This is the only reported
case in which oral spironolactone administration was effective in
weaning a patient with insufficient ANP secretion from intrave-
nous h-ANP infusion, and further studies are needed to establish
the perioperative management for h-ANP–dependent patients.
In summary, we treated a patient with giant atria and a very low
plasma ANP concentration caused by severe MS and TR. After
cardiac surgery, oliguria developed, and continuous intravenous
h-ANP infusion was effective for its postoperative management. It
was difficult to wean the patient from the h-ANP infusion with the
administration of furosemide alone. The RAAS was still activated
long after the termination of CPB, and oral spironolactone admin-
istration was effective in weaning the patient from the intravenous
h-ANP infusion.
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